Johnson & Johnson Appoints Ryan Koors as New Vice President of Investor Relations

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

2026Year5Month1Day,Johnson & Johnson Officially Announces the Appointment of Ryan·Cools (Ryan Koors) as Vice President of Investor Relations (IR), the appointment will take effect on2026Year5Month7Officially effective on [date].Cools will report directly to Executive Vice President and Chief Financial Officer Joseph·J·Volker (Joseph J. Volk) report, replacing the outgoing Darren Snellgrove (Darren Snellgrove). The latter will transition to a biopharmaceutical enterprise.Halozyme, the Chief Financial Officer, embarks on a new chapter in his career.

Volcker emphasized in the statement:"Ryan's appointment fully demonstrates Johnson & Johnson's deep pool of financial talent and its commitment to continuously cultivating leadership. With profound insights into the company’s business and proven financial expertise, Ryan will be the perfect leader for the investor relations function, serving as a vital communication bridge with the investment community. This will help the company further its long-term strategy, achieve accelerated growth, and create shareholder value."

At the age of45Rui'an since the age of2002Since joining Johnson & Johnson in year, has accumulated over20Years of financial management experience, with a career spanning multiple core functional areas such as innovative medicine, R&D, medical technology, and supply chain.In the past three years, he served as the Vice President of Finance and Chief Financial Officer of Johnson & Johnson Innovation Medicine Global R&D, leading strategic financial planning and capital allocation. Prior to that, he also held positions such as Vice President of Medical Technology Surgery, Vice President of Medical Technology Finance, and Vice President of Finance for the Medical Technology Supply Chain, demonstrating excellent cross-departmental collaboration capabilities.

Volker specially thanked Snellgrove for his contributions:"During Darren's tenure, he demonstrated outstanding leadership and professionalism. We sincerely wish him all the best inHalozyme"Embarking on a new journey to achieve greater success."

This personnel change marks a new phase of development for Johnson & Johnson's investor relations team. As a global leader in the healthcare industry, Johnson & Johnson is strengthening its strategic dialogue with the capital markets through the continuous optimization of its management structure.FutureLay a solid foundation for the implementation of strategic planning.